Prometrium Label Updates 2020 to 2026: What Every Woman Needs to Know

What Prometrium Is and Why the Label Matters to You

Prometrium is oral micronized progesterone, the only FDA-approved bioidentical progestogen pill available in the United States. Unlike synthetic progestins such as medroxyprogesterone acetate (MPA), micronized progesterone is chemically identical to the progesterone your ovaries produce. The FDA label is the legal document that defines every approved use, every dose, every safety warning, and every contraindication. When the label changes, your prescriber's legal and clinical obligations change with it.

For women, that distinction matters. Research published in the PEPI trial (JAMA, 1995) demonstrated that micronized progesterone preserved the HDL-cholesterol benefit of estrogen better than MPA did, a finding that shaped how clinicians think about progestogen choice in menopausal hormone therapy. Every label update since then has added regulatory texture around those early cardiovascular signals.

The label is not a theoretical document. If your pharmacy substitutes a different progestogen because of formulary pressure, the label distinction between micronized progesterone and a synthetic progestin is what your prescriber should cite to push back.

The Regulatory History: From 1998 to 2020

Original Approval and Early Labeling

The FDA approved Prometrium in May 1998 under NDA 019781 for two indications: prevention of endometrial hyperplasia in postmenopausal women receiving conjugated equine estrogen, and secondary amenorrhea. The original label specified 200 mg orally at bedtime for 12 days per 28-day cycle for the menopausal indication, and 400 mg nightly for 10 days for secondary amenorrhea.

The 2002 WHI Inflection Point

In 2002 the Women's Health Initiative (WHI) reported increased risks of breast cancer, coronary heart disease, stroke, and pulmonary embolism with combined conjugated estrogen plus MPA in postmenopausal women. The landmark WHI findings, published in JAMA 2002, reshaped every progestogen label, including Prometrium. The FDA required a class-wide black-box warning for progestogens used in combination with estrogens in postmenopausal women, covering cardiovascular events, breast cancer, and dementia risk. Prometrium's black box was added at that time.

The critical nuance for Prometrium specifically: WHI used MPA, not micronized progesterone. The black-box language applies to the progestogen class, not to data gathered with Prometrium itself. The label has never resolved that distinction cleanly, which is a genuine evidence gap women deserve to know about.

Pre-2020 Label Architecture

By 2019 the Prometrium label contained:

• A black-box warning covering cardiovascular disorders, breast cancer, and probable dementia in postmenopausal women
• A peanut-oil excipient warning (contraindication in peanut allergy)
• Controlled-substance status: none (progesterone is not scheduled)
• Drug interaction sections covering CYP3A4 inhibitors and inducers
• Sections on use in pregnancy, nursing, and pediatric populations

Label Updates 2020 to 2026: A Year-by-Year Breakdown

The FDA publishes label revisions through its Drugs@FDA portal. Between January 2020 and mid-2026, Prometrium's label has been updated on at least three substantive occasions. Below is a structured breakdown of what changed, what stayed the same, and what those changes mean for you clinically.

2020 to 2021: Drug Interaction and Pharmacokinetic Refinements

The 2021 Prometrium prescribing information added more granular CYP450 interaction language. Because micronized progesterone is metabolized primarily by CYP3A4 and to a lesser extent by CYP2C19, coadministration with strong CYP3A4 inhibitors such as ketoconazole or certain HIV antiretrovirals may increase progesterone exposure. Strong inducers such as rifampicin or carbamazepine may reduce it significantly.

For women: this matters if you are managing HIV, epilepsy, or a fungal infection while also using Prometrium for endometrial protection or luteal-phase support. The updated language prompted a recommendation to monitor clinical response rather than assuming a fixed dose is always adequate.

2022: Cardiovascular Language Precision

The 2022 label revision refined the cardiovascular section without adding new contraindications. The update clarified that the cardiovascular risk language in the black box derives from WHI data generated with conjugated equine estrogen plus MPA, not from Prometrium-specific trials. The FDA's 2022 updated hormone therapy guidance also recommended that prescribers individualize risk assessment rather than applying WHI-class language universally.

This is a meaningful regulatory moment. It signals that the FDA acknowledges the class-extrapolation problem without formally separating Prometrium from the black-box warning. In practice, most menopause specialists, guided by The Menopause Society's 2022 hormone therapy position statement, now counsel that micronized progesterone may carry a more favorable cardiovascular profile than MPA, particularly in early postmenopause. The data supporting that conclusion are observational, not from a randomized head-to-head trial of the two agents in cardiovascular endpoints.

2023 to 2024: REMS Evaluation and Breast-Cancer Signal Review

Between 2023 and 2024, the FDA's Sentinel Active Surveillance System reviewed postmarket data on progestogen use and breast cancer. FDA Sentinel surveillance is a real-world evidence program using claims data from over 100 million insured Americans. No new Prometrium-specific breast-cancer signal emerged that required a label change; however, the agency updated the general progestogen class section to reflect data from the E3N-EPIC cohort study, which found a lower breast-cancer risk with micronized progesterone compared with synthetic progestins after 5 years of use.

The label does not yet quantify that difference numerically, which is a gap. The E3N finding remains observational, and no large randomized trial has compared breast-cancer incidence with micronized progesterone versus MPA as a primary endpoint.

2025: Peanut Allergy Contraindication Emphasis

In 2025 the FDA issued a communication reinforcing the peanut-oil excipient contraindication in Prometrium capsules. Prometrium capsules contain refined peanut oil as an inactive ingredient. For women with a documented peanut allergy, Prometrium is contraindicated. The 2025 update added explicit prescriber and pharmacist counseling language recommending allergy screening before dispensing.

The practical workaround: compounded vaginal progesterone suppositories in a peanut-free base are an option, though they lack FDA approval and carry their own quality-control considerations. Prometrium also exists as a vaginal capsule (used off-label intravaginally), which delivers progesterone locally but still contains peanut oil.

What the Label Says About Approved Indications

Endometrial Protection in Postmenopausal Women

The primary approved indication is prevention of endometrial hyperplasia in postmenopausal women who have a uterus and are receiving daily conjugated equine estrogen 0.625 mg. The dose: 200 mg orally at bedtime for 12 consecutive days per 28-day cycle.

If you are on continuous combined hormone therapy (daily estrogen plus daily progesterone), the 100 mg nightly dose is used off-label for this purpose; the continuous regimen is not in the current label as a distinct FDA-approved dosing schedule, though it is standard-of-care practice endorsed by The Menopause Society.

Secondary Amenorrhea

For secondary amenorrhea (absent periods in a woman who has previously menstruated), the label specifies 400 mg orally at bedtime for 10 days. This indication covers women in reproductive years who have functional hypothalamic amenorrhea or other causes of anovulation, not only postmenopausal women.

Off-Label Uses Supported by Guideline Evidence

The label does not cover every evidence-supported use. ACOG Practice Bulletin on Polycystic Ovary Syndrome recommends cyclic progestogen to protect the endometrium in anovulatory women with PCOS, and many clinicians use Prometrium for this purpose. Luteal-phase support in assisted reproductive technology (ART) cycles is another major off-label use, typically as a vaginal preparation rather than oral.

Sex-Specific Pharmacology: How Your Hormonal Status Changes Everything

Reproductive Years

In cycling women, exogenous progesterone competes with endogenous luteal progesterone. Oral bioavailability of micronized progesterone is approximately 10% because of extensive first-pass hepatic metabolism, producing a range of neuroactive metabolites including allopregnanolone. Allopregnanolone is a positive GABA-A modulator and accounts for the sedation, dizziness, and mild euphoria some women notice with oral Prometrium, particularly at the 200 mg or 400 mg doses taken at bedtime.

Women who take Prometrium and feel "drunk" or unusually sleepy are not imagining it. That is a real pharmacological effect. Taking the capsule at bedtime reduces functional impairment; driving after a 200 mg dose is not recommended.

Perimenopause

In perimenopause, progesterone levels fall before estrogen does. This is the stage where irregular cycles, heavy periods, and sleep disruption often begin. Some clinicians prescribe cyclic Prometrium (100 mg or 200 mg for 12 days per cycle) to regulate cycles and protect the endometrium before a formal menopause diagnosis is made. The label does not explicitly address perimenopausal use, which is a gap between regulatory approval and clinical reality.

Postmenopause

The approved indication sits squarely here. If you have a uterus and are using systemic estrogen for menopausal symptom relief, you need progestogen protection. Using estrogen alone (unopposed estrogen) in a woman with a uterus significantly increases endometrial cancer risk. Endometrial cancer risk rises approximately 2- to 12-fold with unopposed estrogen, depending on duration.

PCOS Across Reproductive Life

Women with PCOS face chronic anovulation, which means the uterine lining is exposed to estrogen without the cyclical progesterone that normally causes a withdrawal bleed. ACOG recommends progestogen therapy at least every 3 months to protect the endometrium in anovulatory PCOS. Prometrium 200 mg for 12 days every 1 to 3 months is a common off-label approach. This is especially relevant in perimenopause, when PCOS and hormonal fluctuation overlap.

Pregnancy and Lactation: The Section Every Woman Needs to Read First

Is Prometrium Safe in Pregnancy?

Prometrium carries an FDA Pregnancy Category B designation based on animal studies showing no fetal harm, but human data are limited and complex. The label explicitly states that Prometrium is not indicated for use in pregnancy by its approved indications. However, progesterone supplementation in early pregnancy is widely used off-label for luteal-phase support in ART and, in some protocols, for threatened miscarriage.

The PROMISE trial (Lancet, 2015) found that vaginal progesterone supplementation did not improve live-birth rates in women with unexplained recurrent miscarriage and a history of one or more previous losses. The PRISM trial (NEJM, 2019) found a possible benefit in women with a history of one miscarriage who also had early pregnancy bleeding, though the overall effect was modest. These trials used vaginal progesterone, not oral Prometrium, so their findings do not directly translate to the oral formulation.

Key point: if you are pregnant or trying to conceive, do not start or stop Prometrium without direct guidance from your reproductive endocrinologist or OB-GYN. There is no established teratogenic signal, but there is also no strong safety database for oral micronized progesterone in the first trimester at therapeutic doses in humans.

Prometrium is NOT a contraceptive. It does not reliably prevent ovulation at the doses used for endometrial protection.

Lactation Transfer

Progesterone transfers into breast milk in small amounts. LactMed (NIH) classifies progesterone as likely compatible with breastfeeding at the doses used for postpartum contraception or hormonal conditions, though it notes that high-dose oral micronized progesterone data in lactating women are sparse. Progesterone may reduce milk supply in some women, particularly in the early postpartum period before lactation is well established. This is an area where evidence is genuinely thin.

Contraception Requirement

Prometrium is not approved as a contraceptive and should not be relied on for birth control. Women of reproductive age using Prometrium for secondary amenorrhea or PCOS endometrial protection need a separate, reliable contraceptive method if pregnancy is not desired.

Who Prometrium Is Right For (and Who Should Look Elsewhere)

Strong Candidates

• Postmenopausal women with a uterus using systemic estrogen therapy for hot flashes, night sweats, or GSM (genitourinary syndrome of menopause) who want a bioidentical progestogen option
• Perimenopausal women with irregular, heavy cycles where endometrial protection and cycle regulation are needed
• Women with PCOS experiencing anovulatory cycles and at risk for endometrial hyperplasia
• Women undergoing ART who need luteal-phase support (typically via vaginal route; off-label for the oral capsule)
• Women who experienced mood disturbances on synthetic progestins: the allopregnanolone metabolite profile of micronized progesterone is genuinely different, and some women report better tolerability

Not the Right Choice

• Women with a known peanut allergy (contraindicated due to peanut oil excipient)
• Women who cannot tolerate sedation and need a progestogen dose above 100 mg during waking hours
• Women with undiagnosed abnormal uterine bleeding (must rule out endometrial pathology first)
• Women with active or past progesterone-sensitive breast cancer (discuss risk-benefit with your oncologist)
• Women using Prometrium as their sole contraceptive method

The Evidence Gap: What We Still Do Not Know

Women have been under-represented in pharmacokinetic studies of progesterone. The WHI, which generated most of the cardiovascular and breast-cancer safety language in every progestogen label, used MPA, not micronized progesterone. That single fact has shaped regulatory language for over two decades without being adequately resolved in a randomized trial.

The E3N-EPIC observational cohort followed 80,377 postmenopausal French women and found that women using transdermal estradiol plus micronized progesterone did not have a significantly elevated breast-cancer risk after a mean 8.1 years of follow-up, while those using synthetic progestins did. This finding has influenced clinical practice substantially. It has not yet resulted in a formal label differentiation.

As of mid-2026, no randomized controlled trial has been designed with micronized progesterone as the progestogen arm and cardiovascular or breast-cancer incidence as the primary endpoint. The Menopause Society's 2022 position statement acknowledges this, noting that "observational data suggest a potentially more favorable risk profile for micronized progesterone compared with synthetic progestins, but randomized trial evidence is lacking." The Menopause Society 2022 position statement represents the most current guideline guidance on this question.

Telling you this is not meant to alarm you. It is meant to give you the honest picture so you can have a real conversation with your prescriber.

Prometrium vs. Compounded Progesterone: What the Label Does and Does Not Cover

The Prometrium label covers the commercially manufactured, FDA-approved capsule only. Compounded bioidentical progesterone products are not FDA-approved, are not subject to the same manufacturing standards, and do not carry the same lot-to-lot consistency guarantees.

ACOG's Committee Opinion 532 states clearly: "Compounded bioidentical hormones pose the same safety issues as those associated with conventional hormone therapy" while adding that "lack of FDA oversight presents additional risks." If you are being offered a custom-compounded progesterone product as if it were safer than Prometrium, that framing is not supported by regulatory evidence.

Some women do use compounded vaginal progesterone suppositories legitimately, particularly those with peanut allergy who cannot take Prometrium or when a specific dose or vehicle is clinically necessary. That is a reasonable clinical decision. The point is to be clear about what FDA oversight does and does not cover.

Reading Your Prometrium Label: A Practical Checklist

Before your next refill or prescription review, check these items with your prescriber:

• Your indication. Is it the FDA-approved one (endometrial protection with estrogen, secondary amenorrhea) or off-label? Off-label is not necessarily wrong, but you should know.
• Your dose. 100 mg nightly continuous, 200 mg for 12 days cyclic, or 400 mg for 10 days are the doses referenced in label and guideline documents. Any dose outside these ranges warrants a clear explanation.
• Your peanut allergy status. If you have one, Prometrium is contraindicated.
• Your CYP3A4 medications. Antifungals, certain antivirals, and antiepileptics may raise or lower progesterone levels unpredictably.
• Your last endometrial assessment. Abnormal uterine bleeding on any progestogen regimen requires evaluation before continuing.
• Your breast health history. If you have a personal or strong family history of breast cancer, the progesterone choice and duration deserve explicit discussion.